Released Nov 6, 2026, before the open
10-Q filed Nov 6, 2026, 37 days after period end · 0001193125-26-451797
For the three months ended September 30, 2026, Minerva recorded GAAP net income of $100.7 million, or $1.94 per basic share and $(0.19) per diluted share, compared to a net loss of $2.7 million, or $(0.36) per basic and diluted share, for the three months ended September 30, 2025.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | $100.75M | -$2.74M | $22.51M | -$7.82M |
| EPS Diluted | -$0.19 | -$0.36 |
Minerva Neurosciences, Inc. · CIK 1598646 · Engraved from SEC EDGAR
| $2.97 |
| -$1.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Minerva reported GAAP net income of $100.7 million for the three months ended September 30, 2026, driven by a $109.6 million non-cash gain on the warrant liability.¶1
For the nine months ended September 30, 2026, Minerva recorded a GAAP net loss of $7.2 million, or $(0.45) per diluted share.¶2
R&D expense was $5.2 million for the three months and $17.6 million for the nine months ended September 30, 2026, higher than the prior year primarily due to C19 trial expenses.¶3
Cash, cash equivalents, marketable securities and restricted cash were approximately $77.0 million at September 30, 2026.¶4
Topline efficacy data from Phase A of the C19 Study is expected in 2H 2027.¶5